Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

NCT02001688 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Alpha-1 Antitrypsin Deficiency

Interventions

DRUG: Kamada-AAT for Inhalation, 80mg
DRUG: Placebo
DRUG: Kamada-AAT for Inhalation, 160mg

Sponsor

Kamada, Ltd.